This is supported by our study as well as by Li and colleagues, who reported that 93% of patients with detectable pre-treatment plasma EBV DNA and high PDL1 expression were associated with a worse prognosis and multiple studies reporting LAG3 expression to be enriched in dysfunctional T cells in NPC tumors [11,39,46]. The gene discussed is LAG3; the disease is nasopharyngeal carcinoma.